scispace - formally typeset
S

Srilakshmi Yalavarthi

Researcher at University of Michigan

Publications -  58
Citations -  8594

Srilakshmi Yalavarthi is an academic researcher from University of Michigan. The author has contributed to research in topics: Neutrophil extracellular traps & Antiphospholipid syndrome. The author has an hindex of 30, co-authored 52 publications receiving 6164 citations.

Papers
More filters
Journal ArticleDOI

Neutrophil extracellular traps in COVID-19.

TL;DR: Sera from patients with COVID-19 have elevated levels of cell-free DNA, myeloperoxidase(MPO)-DNA, and citrullinated histone H3 (Cit-H3); the latter two are highly specific markers of NETs, which may contribute to cytokine release and respiratory failure.
Journal ArticleDOI

NETs Are a Source of Citrullinated Autoantigens and Stimulate Inflammatory Responses in Rheumatoid Arthritis

TL;DR: Investigation of whether aberrant NETosis occurs in RA, determined its triggers, and examined its deleterious inflammatory consequences implicate accelerated NETosis in RA pathogenesis, through externalization of citrullinated autoantigens and immunostimulatory molecules that may promote aberrant adaptive and innate immune responses in the joint and in the periphery, and perpetuate pathogenic mechanisms in this disease.
Journal ArticleDOI

Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis

TL;DR: It is demonstrated that mast cells and neutrophils, not T cells, are the predominant cell types that contain IL-17 in human skin, and that IL-23 and IL-1β can induce mast cell extracellular trap formation and degranulation of human mast cells.
Journal ArticleDOI

A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Vascular Damage and Synthesizes Type I IFNs

TL;DR: Lupus LDGs are proinflammatory and display pathogenic features, including the capacity to synthesize type I IFNs, which may play an important dual role in premature cardiovascular disease development in systemic lupus erythematosus by simultaneously mediating enhanced vascular damage and inhibiting vascular repair.